Phase I study of H3B-6545 in patients (pts) with estrogen receptor-positive (ER plus ) breast cancer

被引：0
|
作者：
Ono, M. [1 ]
Kogawa, T. [1 ]
Kitano, S. [1 ]
Shimoi, T. [2 ]
Yamamoto, K. [2 ]
Kobayashi, S. [3 ]
Ichikawa, Y. [3 ]
Yamaguchi, K. [4 ]
Otake, Y. [3 ]
Hojo, S. [5 ]
Yonemori, K. [2 ]
机构：
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Adv Med Dev Ctr, Tokyo, Japan
[2] Natl Canc Ctr, Dept Med Oncol, Tokyo, Japan
[3] Eisai & Co Ltd, DHBL, Clin Evidence Generat Fulfillment, Japan & Asia Clin Dev,Dept Oncol, Tokyo, Japan
[4] Eisai & Co Ltd, DHBL, Clin Evidence Generat Fulfillment, Clin Pharmacol Sci Dept, Tokyo, Japan
[5] Eisai & Co Ltd, DHBL, Clin Evidence Generat Fulfillment, Clin Data Sci Dept, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.190
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
55O
引用
收藏
页码：S1487 / S1487
页数：1
相关论文
共 50 条
  • [21] A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER plus ) breast cancer
    Baselga, J.
    Morales, S. M.
    Awada, A.
    Blum, J. L.
    Tan, A. R.
    Ewertz, M.
    Cortes, J.
    Moy, B.
    Ruddy, K. J.
    Haddad, T.
    Ciruelos, E. M.
    Vuylsteke, P.
    Ebbinghaus, S.
    Im, E.
    Eaton, L.
    Prathiraja, K.
    Gause, C.
    Mauro, D.
    Rugo, H. S.
    CANCER RESEARCH, 2013, 73
  • [22] A phase I study of continuous (Con) and intermittent (Int) AZD2014 plus fulvestrant (F) in patients (pts) with estrogen receptor (ER plus ) metastatic breast cancer (BC).
    Hamilton, Erika Paige
    Patel, Manish R.
    Gluck, W. Larry
    Weise, Amy M.
    Pant, Shubham
    Jones, Suzanne Fields
    LoRusso, Patricia
    Kittaneh, Muaiad
    Cosulich, Sabina
    Harrington, Elizabeth A.
    Littlewood, Gillian
    Oelmann, Elisabeth Maria
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] THE USE OF ADJUVANT ENDOCRINE THERAPY IN OLDER WOMEN WITH ESTROGEN RECEPTOR-POSITIVE (ER plus ) BREAST CANCER (BC)
    Aapro, M.
    Crivellari, D.
    ANNALS OF ONCOLOGY, 2008, 19 : 208 - 209
  • [24] Acquired RBI mutations in estrogen receptor-positive (ER plus ) clinically advanced and metastatic breast cancer (MBC).
    McGregor, Kimberly
    Sokol, Ethan
    Danziger, Natalie
    Pavlick, Dean
    Elvin, Julia Andrea
    Vergilio, Jo-Anne
    Killian, Jonathan Keith
    Lin, Douglas I.
    Williams, Erik Abraham
    Ramkissoon, Shakti H.
    Severson, Eric Allan
    Hemmerich, Amanda
    Duncan, Daniel
    Huang, Richard
    Chung, Jon
    Reddy, Venkataprasanth P.
    Venstrom, Jeffrey
    Schrock, Alexa Betzig
    Alexander, Brian Michael
    Ross, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer
    Jhaveri, Komal
    Juric, Dejan
    Yap, Yoon-Sim
    Cresta, Sara
    Layman, Rachel M.
    Duhoux, Francois P.
    Terret, Catherine
    Takahashi, Shunji
    Huober, Jens
    Kundamal, Nicole
    Sheng, Qing
    Balbin, Alejandro
    Ji, Yan
    He, Wei
    Crystal, Adam
    De Vita, Serena
    Curigliano, Giuseppe
    CLINICAL CANCER RESEARCH, 2021, 27 (21) : 5760 - 5770
  • [26] A Phase 2 Study of Ridaforolimus (RIDA) and Dalotuzumab (DALO) in Estrogen Receptor Positive (ER plus ) Breast Cancer.
    Lu, B. D.
    Blum, J. L.
    Cortes, J.
    Rugo, H. S.
    Swanton, C.
    Eaton, L.
    Song, Y.
    Zhang, T.
    Ebbinghaus, S. W.
    Baselga, J.
    CANCER RESEARCH, 2011, 71
  • [27] Development of H3B-6545, a first-in-class oral selective ER covalent antagonist (SERCA), for the treatment of ERaWT and ERaMUT breast cancer
    Korpal, Manav
    Furman, Craig
    Puyang, Xiaoling
    Zhang, Zhaojie
    Wu, Zhenhua
    Banka, Deepti
    Das, Subhasree
    Destenaves, Benoit
    Gao, Lei
    Hamilton, Erika
    Hao, Ming-Hong
    Irwin, Sean
    Johnston, Stephen
    Joshi, Jaya J.
    Juric, Dejan
    Kim, Amy
    Tuong-Vi Nguyen
    Pipas, Marc
    Pluard, Timothy
    Rimkunas, Victoria
    Rioux, Nathalie
    Schindler, Joanne
    Smith, Peter
    Thomas, Michael
    Wang, John
    Wang, Judy S.
    Warmuth, Markus
    Yao, Huilan
    Yao, Shihua
    Yu, Lihua
    Vaillancourt, Frederic H.
    Bolduc, David M.
    Larsen, Nicholas A.
    Zheng, GuoZhu
    Prajapati, Sudeep
    Sahmoud, Tarek
    Gualberto, Antonio
    Zhu, Ping
    CANCER RESEARCH, 2021, 81 (04)
  • [28] Progression of genomic signatures in local and metastatic estrogen receptor-positive (ER plus ) breast cancer: Relevance to palliative treatment
    Symmans, William Fraser
    Andreopoulou, Eleni
    Booser, Daniel J.
    Hatzis, Christos
    Wallace, Michael J.
    Zhang, Ya
    Gong, Yun
    Ignatiadis, Michail
    Sotiriou, Christos
    Andre, Fabrice
    Peintinger, Florentina
    Regitnig, Peter
    Marth, Christian
    Desmedt, Christine
    Loi, Sherene
    Moulder, Stacy L.
    Hortobagyi, Gabriel N.
    Pusztai, Lajos
    Valero, Vicente
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer
    Baselga, Jose
    Morales, Serafin M.
    Awada, Ahmad
    Blum, Joanne L.
    Tan, Antoinette R.
    Ewertz, Marianne
    Cortes, Javier
    Moy, Beverly
    Ruddy, Kathryn J.
    Haddad, Tufia
    Ciruelos, Eva M.
    Vuylsteke, Peter
    Ebbinghaus, Scot
    Im, Ellie
    Eaton, Lamar
    Pathiraja, Kumudu
    Gause, Christine
    Mauro, David
    Jones, Mary Beth
    Rugo, Hope S.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 163 (03) : 535 - 544
  • [30] A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer
    José Baselga
    Serafin M. Morales
    Ahmad Awada
    Joanne L. Blum
    Antoinette R. Tan
    Marianne Ewertz
    Javier Cortes
    Beverly Moy
    Kathryn J. Ruddy
    Tufia Haddad
    Eva M. Ciruelos
    Peter Vuylsteke
    Scot Ebbinghaus
    Ellie Im
    Lamar Eaton
    Kumudu Pathiraja
    Christine Gause
    David Mauro
    Mary Beth Jones
    Hope S. Rugo
    Breast Cancer Research and Treatment, 2017, 163 : 535 - 544
12345